Trigeminal neuralgia, also known as tic douloureux, is a chronic pain condition that affects the trigeminal or 5th cranial nerve, which carries sensation from the face to the brain. It causes episodes of sharp, shock-like pain in the areas of the face served by this nerve such as lips, eyes, nose, scalp, forehead and cheek. The attacks can vary from mild to severe and are often triggered by everyday activities like eating, talking and brushing teeth. Medication, surgery and other procedures are used to treat trigeminal neuralgia.

The global trigeminal neuralgia treatment market is estimated to be valued at US$ 242.95 Mn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The global trigeminal neuralgia treatment market is expected to witness significant growth during the forecast period (2023-3030). One of the major drivers of the market is the growing prevalence of trigeminal neuralgia diseases across the globe. As per the National Institutes of Health (NIH), trigeminal neuralgia affects approximately 150,000 Americans at any given time. Women are nearly twice as likely as men to develop this condition. The disease prevalence also increases with age, with most cases being diagnosed between the ages of 40 and 70 years. Hence, the aging population is another factor fueling the market growth. Furthermore, advancements in surgical treatments such as gamma knife radiosurgery and percutaneous balloon compression therapy have reduced procedural invasiveness and enhanced patient outcomes, thereby augmenting the adoption of these procedures over the years. Moreover, increasing research and development activities focused on developing novel therapies for trigeminal neuralgia are anticipated to present lucrative opportunities for key players operating in the market during the forecast period.

SWOT Analysis
Strength:
- Growing aging population and rising prevalence of trigeminal neuralgia drives the market growth.
- Launch of novel drugs with minimal side effects will fuel the demand.
- Increasing awareness regarding treatment options available boosts the trigeminal neuralgia treatment market.
Weakness:
- High costs associated with surgery and interventional procedures restrain the market growth.
- Side effects associated with drugs hamper preference and adherence.
Opportunity:
- Emergence of developing nations with large population offers huge untapped potential.
- Ongoing research for better drugs and minimally invasive treatments widen the scope.
Threats:
- Less number of approved drugs limit the market growth.
- Lack of skilled professionals for surgeries act as a challenge.

Key Takeaways

Global Trigeminal Neuralgia Treatment Market Growth is expected to witness high growth over the forecast period.

Regional analysis: North America currently dominates the market and is expected to continue its dominance during the forecast period. Increasing prevalence of trigeminal neuralgia in the US and Canada coupled with high healthcare spending capacity drives the regional market.

Key players operating in the trigeminal neuralgia treatment market are F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Abbott (U.S.), Hikma Pharmaceuticals PLC (U.K.), Allergan (Ireland), Eli Lilly and Company (U.S.), Aurobindo Pharma (India), Lupin (India), SHIONOGI & Co., Ltd. (Japan), AbbVie Inc. (U.S.).

Get More Insights On This Topic: https://www.pressreleasebulletin.com/global-trigeminal-neuralgia-treatment-market-size/